Lorraine McDonald, MBA’s Post

Learn about how Ortho-tag’s nanosensors can enhance pH monitoring around orthopaedic implants to reduce the incidence of Periprosthetic Joint Infection (PJI). This article explains how harnessing the power of this breakthrough technology will advance diagnostics, improve patient outcomes, and reduce healthcare costs. Join us on our journey at www.orthotag.com or contact us at info@orthotag.com to learn more about our system and how to invest. #pHsensing #healthcare  #medicaldevice#earlydetection #diseasemanagement #startup #venturecapital #funding#investors

Check out our latest article in the Journal of Orthopaedic Experience & Innovation, “In My Experience…The Current State of Private Equity in Orthopaedics.” Thomas Cunningham and John M. Tiedmann Jr. examine how private equity is transforming orthopaedic practices through improved efficiency, expanded services, and advanced technologies. While these investments can enhance growth, they also raise concerns about potential compromises in patient care and increased financial pressures. The piece provides a balanced view of private equity's benefits and challenges, considering its future impact on orthopaedics and the healthcare system.

Transforming Orthopaedic Therapy Across Borders We are excited to share a case study that showcases our commitment to driving global healthcare forward. Spearheading a strategic journey, we've paved the way for an EU-based med-tech startup's Orthopaedic Therapy Device from its initial stages to international markets.   🌍 Challenge: Navigating the intricate web of international reimbursement strategies for a device set to revolutionise orthopaedic trauma therapy and rehabilitation.   🔍 Solution: Leveraging inXso's expertise, we embarked on a meticulous analysis and strategic formulation that spanned across continents. From comprehensive market assessments in Europe to exploring avenues in key global markets, our mission was to identify the optimal path for product launch and revenue generation.   💡 Impact: Our efforts culminated in a robust international reimbursement strategy, pinpointing six countries for successful market entry. This strategic endeavour not only promises a brighter future for orthopaedic care but also ensures a swift journey to market success and revenue realisation for our clients.   Dive deeper into our strategic approach and the transformative impact of this project! #medicalinnovation #reimbursement #OrthopaedicInnovation #HealthcareStrategy #MedTech #inXso  #InternationalMarketAccess #inXsoSuccess

Check out our latest article in the Journal of Orthopaedic Experience & Innovation, “In My Experience…The Current State of Private Equity in Orthopaedics.” Thomas Cunningham and John M. Tiedmann Jr. examine how private equity is transforming orthopaedic practices through improved efficiency, expanded services, and advanced technologies. While these investments can enhance growth, they also raise concerns about potential compromises in patient care and increased financial pressures. The piece provides a balanced view of private equity's benefits and challenges, considering its future impact on orthopaedics and the healthcare system.

📄 Research Report   Petra Capital Pty Ltd has released an independent analyst report, forecasting Orthocell’s potential to reach A$1.28 per share. Highlighting the attractive commercial opportunity for SmrtGraft™, Orthocell’s tendon repair product, the author notes: “OCC’s SmrtGraft™ tendon product application for approval in Australia opens up a potential third product revenue stream for the CelGro™ platform and is currently not in our forecasts. For use by Orthopaedic surgeons, we see distribution as well as manufacturing synergies with OCC’s Remplir nerve product. As such, it represents a potential attractive revenue stream without much additional cost. With OCC on track for US approval of Remplir in 1QCY25, our TP of $1.28/sh offers >3x upside.”   Take a closer look 👉 https://lnkd.in/gCwyNn8F   $OCC #innovation #biotech #pharma #regenerativemedicine #healthcare

The medical device sector requires different expertise compared to pharmaceuticals. Alkem Labs will need to acquire talent or partner with existing players to be successful. The medical device market is already well-established, with strong domestic and international players. Alkem Labs will face competition in capturing market share. Developing and commercializing new medical devices often involves significant R&D investments.

Orthopedics Trend #17: A Shift to Long-Term Thinking Largely due to the new financial environment, startups are focusing on building substantial, enduring businesses, and avoiding the pitfalls of premature exits. A second order effect of long-term thinking is that CEOs are strategizing for financial sustainability, aiming for cash flow positivity or breakeven in a growth-aligned manner. Explore 21 more trends redefining the orthopedics landscape here - https://lnkd.in/efNSUCTi

Why the 510(k) Pathway is a Game-Changer for Small Orthopedic Implant Businesses For small businesses in the orthopedic implant space, navigating regulatory approval can be daunting. But, the FDA’s 510(k) process offers a more accessible pathway to market entry, especially for innovative startups. 💡 Cost-Effective & Efficient: The 510(k) submission is generally less expensive and faster compared to premarket approval (PMA). This makes it ideal for small businesses with limited budgets who are still aiming to bring life-changing medical devices to market. 🦾 Less Burdensome Clinical Requirements: Unlike PMA, which often requires extensive clinical trials, the 510(k) process usually requires demonstrating that your device is "substantially equivalent" to an already cleared device. This reduces development time and costs, while maintaining high safety and efficacy standards. 🌍 Early Market Access: Small orthopedic implant manufacturers can leverage the 510(k) to enter the market faster, allowing them to gain an early foothold, build brand recognition, and generate revenue sooner. For innovative solutions in orthopedic implants, the 510(k) pathway opens up tremendous opportunities to create impact while streamlining regulatory compliance. #MedTech #Orthopedics #FDA510k #Innovation #Startups #Compliance

OrthoLazer is an exclusive franchise opportunity for select orthopedic surgeons, physicians, and other pain management specialists to offer their patients and their communities an effective, opioid-free, alternative pain management option. Our system of franchise implementation includes an Onboarding Roadmap and Franchise Success Team that eliminates all the guesswork – and much of the legwork – involved in opening your own OrthoLazer Center. In this video, OrthoLazer Founder and Chief Medical Officer, Dr. Scott Sigman, talks about franchising opportunities in more depth. If you’ve ever thought about opening your own OrthoLazer Orthopedic Laser Therapy Center – or developing another revenue stream – you need to watch this video. Let us know what you think! #drscottsigman #followthefro #lasertherapy #painmanagement #painreleif #medicalfranchise #medtech

Generally right, but specifically wrong. I met an orthopedic entrepreneur who did every right. This Founder/CEO was in the right space at the right time, but missed a key detail. It turns out that he was generally right but specifically wrong. So he failed. Generally right, but specifically wrong. Consider this illustrative example: this same Founder/CEO shared a story about a distant relative with a massive farm in Nebraska, strategically positioned along the proposed path of the new transcontinental railway. Anticipating a windfall, the family expanded their land holdings to ensure the railway's passage through their property. Yet, in a surprising twist, the railway planners rerouted the line 30 miles away, bypassing the farm entirely. Generally right, but specifically wrong. Another example is Colonel Sanders, the visionary behind KFC. Sanders transformed a simple gas station into a bustling restaurant, capitalizing on his unique fried chicken recipe. His establishment thrived, earning him the title of Kentucky Colonel. However, the construction of Interstate 75 diverted traffic away from his restaurant, causing a dramatic downturn in business and forcing him to sell. Once again, a broad vision met a stumbling block that couldn't have been foreseen. Generally right, but specifically wrong. A more industry-specific instance is the story of Amedica, a company with the ambition to revolutionize hip replacements with a zero-debris, indestructible ceramic material. The founder, AK, introduced silicon nitride into the orthopedic field, a material with promising applications in joint articulation. Amedica, now rebranded as SINTX, had the makings of a billion-dollar enterprise but was blindsided by an insurmountable regulatory pathway, resulting in a current valuation of merely $3M. This underscores the theme: a general right direction does not immunize against specific failures. Generally right, but specifically wrong. I worry about the current landscape of orthopedic startups venturing into innovative territories like additive manufacturing, AI, robotics, and augmented reality. They stand on the cusp of transforming orthopedics forever and having great financial outcomes, yet the lesson remains—being generally right is not enough.